Grünenthal Acquires Stivarga Cancer Treatment From Bayer
Aachen, Germany, September 21, 2026 Grünenthal has announced an agreement with Bayer AG to acquire Stivarga® (regorafenib), an established...
liver cancer
Advertisement
Can-Fite Reports Longer Overall Survival in Phase III Liver Cancer Study
RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
CancerVax Activates Human Killer T-Cells Against Cancer
LEHI, Utah, August 6, 2026 CancerVax announced a significant preclinical milestone with new in vitro findings demonstrating that its...
Leads Biolabs Advances Opamtistomig Phase II Trial in First-Line Liver Cancer
NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...
Advertisements
Elevar Receives FDA Complete Response Letter
FORT LEE, N.J., July 10, 2026 Elevar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has issued...
Can-Fite Reports Positive Phase 2a Namodenoson Safety Datar
Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...
OriCell’s Ori-C101 Advances to Phase II Trial in Liver Cancer
SHANGHAI, China, June 8, 2026 OriCell Therapeutics has achieved a major regulatory and clinical milestone with the National Medical...
AngioDynamics Expands Medicare Access for NanoKnife Cancer Therapy
Latham, New York | May 28, 2026 AngioDynamics announced that Palmetto GBA has issued a final Local Coverage Determination...
AstraZeneca Unveils Major ASCO 2026 Cancer and Rare Disease Data
CAMBRIDGE, UK, 22 May 2026 AstraZeneca announced a major scientific showcase at the upcoming ASCO Annual Meeting 2026, highlighting...
Advertisement
